Population-based screening by Biohit GastroPanel[®] biomarkers practically eliminates the risk of gastric cancer during a long-term follow-up
Biohit GastroPanel® is a unique Finnish innovation intended for a non-invasive diagnosis of the patients with dyspeptic (upper abdominal) complaints to confirm or exclude the presence of Helicobacter pylori (Hp) infection and atrophic gastritis (AG) (1,2). Similarly, GastroPanel® is the only test on the market that accurately monitors the regulation of the acid output in the stomach.
Because Hp and AG are the most important risk conditions for gastric cancer (GC), GastroPanel® blood test is also particularly applicable for population-based screening of asymptomatic individuals for the risk of gastric cancer (GC) (1,2,3,4). Indeed, such population-based studies assessing the value of GastroPanel® biomarkers as predictors of GC have been reported from different geographic regions (5), including the GC high-risk areas of China (6,7).
A significant confirmatory evidence to the previous studies on GastroPanel® biomarkers as predictors of GC was provided by a recently published population-based screening study from the Republic of Karachaevo-Cherkessia (Russian Federation) (8). In this longitudinal cohort study from the Department of Therapy, Medical Institute (North Caucasus State Academy for Humanities and Technologies, Cherkessk), Prof Kotelevets and his associates used a case-control setting by prospectively following-up two groups of subjects (2 220 patients in both groups) for 7 years to monitor for the development of incident GC in these two groups.
Adjunct professor Minna Mäki, PhD, Director of R & D, Biohit Oyj: “In this study, the authors designed a prospective cohort study where two groups of 2.220 subjects were prospectively followed-up for 7 years. The original study group of 2.847 people (aged > 40 years) underwent serological testing by GastroPanel® (including postprandial G-17s and other markers in fasting samples). In seven years, 627 subjects were lost to follow-up, leaving a total of 2.220 subjects for final evaluation. The control group (n=2.220) was built up by randomizing the population (n=212.565) of the Karachay-Cherkess Republic, aged >40 years. These subjects in the control group did not receive any serological screening by GastroPanel test (8). Altogether, 74.9 % of the study subjects tested Hp-positive by GastroPanel test, and 75 (2.6 %) showed multifocal AG and subjected to gastroscopy and biopsies. Both figures are concordant with the studies run by Biohit Oyj in countries with equally high risk for Hp-infection (summarized in 2).”
CEO Semi Korpela, Biohit Oyj: “This well-designed new cohort study provides additional confirmatory evidence to the previously published similar type of studies, where GastroPanel® biomarkers were shown to be significant independent predictors of incident GC (5,6,7). The single most important result of this study (8) is the fact that none of the subjects (0/2.220) who were screened by GastroPanel 7 years earlier (and adequately monitored for the detected abnormalities; Hp and AG) developed an incident GC, whereas in the control population (n=212.565) a total of 410 new CG cases were detected, translating to the incidence of 4.3/2.220. The authors conclude that in their study, 4.3 lives were saved out of 2.220 GastroPanel® tested persons. Interestingly this corroborates to the health economic modelling in Finland, suggesting that a huge amount of health care costs could be saved by systematic screening by GastroPanel® (1,2,9,10)”.
1. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K and Sung J: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47: 136-147.
2. Syrjänen K, Eskelinen M, Peetsalu A, Sillakivi T, Sipponen P, Härkönen M, Paloheimo L, Mäki M, Tiusanen T, Suovaniemi O, DiMario F, Fan ZP. GastroPanel® Biomarker Panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res 2019;39: 1091-1104.
3. Syrjänen K: A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36: 5133-5144.
4. Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A and Bazzoli F: Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017;46: 1-11.
5. Kurilovich SA, Belkovets AV, Reshetnikov OV, Openko TG, Malyutina SK, Ragino YI, Scherbakova LV, Leja M, Paloheimo L, Syrjänen K, Voevoda MI. Stomach-specific biomarkers (GastroPanel) can predict the development of gastric cancer in Caucasian population: A longitudinal nested case-control study in Siberia. Anticancer Res 2016;36: 247-254.
6. Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X and Yuan Y: A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol 2017;112: 704-715.
7. Cai Q, Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y et al. and Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA). Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut 2019;0:1–12. doi:10.1136/gutjnl-2018-317556
8. Kotelevets SM, Chekh SA. Screening, monitoring, and treatment of precancerous
atrophic gastritis in the prospective study for seven years. Asian Pac J Cancer Prev 2020;21(2): 331-336.
9. www.biohithealthcare.com /Links: State of the art diagnosis of Helicobacter pylori and State of the art GastroPanel and Acetium innovations for the unmet need.
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com